Good morning, ladies and gentlemen. I am Ian F. Smith, Chief Executive Officer of Stoke Therapeutics. It is a pleasure to welcome you to our annual meeting of stockholders. Thank you for joining us today. We're excited to be hosting our virtual annual meeting, which allows us to be more inclusive and reach a greater number of our stockholders. We'll conduct the business portion of the meeting first and answer questions at the end of the meeting. Though we may not be able to answer every question, we will do our best to provide a response to as many as possible. In keeping with the digital approach to this year's meeting, it is now 9:00 A.M. Eastern Time on June 3rd, 2026, and this meeting is officially called to order. Now I'd like to introduce the following members of the board of directors who are with us this morning. Myself, Ian F. Smith, Jennifer Burstein, Dr. Adrian Krainer, Dr. Arthur Levin, Dr. Arthur Tzianabos, Julie Anne Smith, Dr. Ed Kaye, and Dr. Clare Kahn. I'd like to also introduce our corporate officers who are with us this morning. Thomas Leggett, our Chief Financial Officer, will be acting as Inspector of Elections, and Jonathan Allan, our General Counsel and Corporate Secretary. I will serve as chair of this meeting. I also want to introduce Effie Toshav of Fenwick & West LLP, our legal counsel, who will also act as secretary of the meeting and keep the minutes, and Lee Van Horn of Ernst & Young LLP, our independent registered public accountants. We will now conduct the formal business matters of the meeting. For this part of the meeting, Mr. Allan will conduct the vote of the stockholders on the matters to be considered today. After adjournment, we will have a question and answer period. Thank you, Ian. April 7th, 2026, was fixed by the board of directors as the record date for the proposals to be voted on at this meeting. Only holders of Stoke's common stock as of the close of business on the record date are entitled to receive notice of and to vote at this meeting. I present to this meeting an affidavit of Joanne Vogel, manager, Broadridge Financial Solutions, Inc., attesting that a notice of the meeting, together with a proxy statement and proxy, were mailed on or about April 22nd, 2026, to each holder of the common stock of Stoke as of the close of business on the record date. The affidavit of mailing of the notice will be attached to the minutes of this meeting. A certified list of the holders of the issued and outstanding shares of Stoke's common stock as of the close of business on the record date is available for inspection upon request. If there is any stockholder present who has not returned a proxy or who desires to revoke a proxy and vote online, that stockholder should do so at this time so that a final tally of the number of shares present can be calculated. The Inspector of Elections has examined the proxies received and reports that 55,174,913 shares, or approximately 88.6% of the total shares of common stock of Stoke entitled to vote, are represented by proxies or in person at this meeting. A majority of the votes entitled to be cast are represented at this meeting, either in person or by proxy. A quorum is therefore present, and the meeting may now proceed. I will now review the agenda and voting procedures. We have three proposals on which the stockholders will be voting. Proposal number one is the election of three Class I directors to serve a three-year term which will expire at the 2029 annual meeting of stockholders. Proposal number two is the ratification of the appointment of our independent registered public accounting firm. Proposal number three is the approval on an advisory basis of the compensation of our named executive officers. If you have previously returned a proxy or voted by phone or through the internet and do not wish to revoke your proxy or change your vote, then you do not need to vote at this meeting. Your vote has already been included in the proxy count. If you did not return a proxy or wish to change your vote, you can do so now through the online portal. We will collect these proxies at the end of the formal business portion of the meeting. Proposal number one is the nomination and election of three Class I directors. The board of directors has nominated each of Dr. G. Clare Kahn, Dr. Adrian Krainer, and Julie Anne Smith to be elected as directors of the company for the next three years and until their successor is duly elected and qualified, or until their earlier resignation or removal. The vote required for proposal number one to elect the Class I directors is a plurality of the votes cast, which means that the three individuals nominated for election to the board of directors at the meeting receiving the most affirmative for votes of the shares present or represented at this meeting will be elected. Our bylaws require that a stockholder provide advance notice of their intent to nominate persons as directors. No such notice was received. Accordingly, I declare the nominations for directors closed. Proposal number two is to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. The vote required for proposal number two to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31st, 2026, is an affirmative for vote of the majority of the shares present or represented at this meeting. Proposal number three is to approve on a non-binding advisory basis the compensation of our named executive officers as disclosed in the proxy statement. The vote required for proposal number three to approve the compensation of our named executive officers, as disclosed in the proxy statement, is an affirmative for vote of the majority of shares present or represented at this meeting. I'll now hand it back over to Mr. Smith. Because no further business is scheduled to come before the stockholders, it is now approximately 9:06 A.M. on June 3rd, 2026. The polls are now open. Any stockholder who hasn't yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instructions there. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their vote do not need to take any further action. Now that everybody has had the opportunity to vote, I declare the polls for each matter voted upon at this Annual Stockholders Meeting closed. Thank you, Ian. Based on the results as tabulated by the Inspector of Elections, G. Clare Kahn, PhD, Adrian Krainer, PhD, and Julie Anne Smith are the three nominees on the ballot who received the highest number of affirmative votes cast, therefore, each nominee has been elected to the board of directors. Based on the results as tabulated by the Inspector of Elections, Ernst & Young LLP has been ratified as Stoke's independent registered public accounting firm for the fiscal year ending December 31st, 2026, by an affirmative for vote. Based on the results as tabulated by the Inspector of Elections, the compensation of our named executive officers, as disclosed in the proxy statement, have been approved by an affirmative for vote. Ian, I'll hand the meeting back to you for an adjournment. Thank you, John. This concludes the business portion of the meeting. There being no further business to conduct, I hereby declare that the 2026 annual meeting of stockholders of Stoke Therapeutics is now adjourned. At this time, we would like to answer stockholders' questions that may be entered today on the web portal. Please note we will attempt to answer as many questions as time allows, but only questions that are germane to the meeting will be addressed. Please feel free to state your question to management generally or to a specific member of Stoke's management team or to our accountant. Before doing so, I would like to remind everybody that during the course of this annual meeting of stockholders, we may make projections or other forward-looking statements regarding future events or the future financial performance of the company. I wish to caution you that these statements are only predictions and that actual events or results may differ materially. We are under no obligation to update or revise any forward-looking statements. I refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company's annual report as filed on Form 10-K for the year ended December 31st, 2025, and the company's quarterly report as filed on Form 10-Q for the quarter ended March 31st, 2026. These contain important factors and a discussion of risks that could cause the actual results to differ materially from those described in our projections or forward-looking statements. Copies of our 10-K for the year ended December 31st, 2025, and our 10-Q for the quarter ended March 31st, 2026, can be found on our website under the investor relations page. Not seeing any questions, we will now conclude the question and answer session. I would like to thank you all very much for attending our 2026 annual meeting of stockholders.